AbCellera Biologics (NASDAQ:ABCL) Releases Earnings Results, Beats Estimates By $0.04 EPS

Key Points

• AbCellera reported quarterly EPS of -$0.13, beating analyst expectations of -$0.17, while revenue of $10.64 million topped estimates of $8.41 million.
• Its ABCL635 Phase II study showed an 83% reduction in daily moderate-to-severe hot flashes after four weeks, compared with 33% for placebo; the company expects to advance the drug into late-stage development in 2027.
• Following a $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and said it has funding for at least three years of pipeline investment.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04, FiscalAI reports. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The company had revenue of $10.64 million for the quarter, compared to analyst estimates of $8.41 million.

Here are the key takeaways from AbCellera Biologics' conference call:

• AbCellera reported strong four-week Phase II results for ABCL635, with an 83% reduction in daily moderate-to-severe hot flashes versus 33% on placebo, and no clear gastrointestinal or liver-toxicity signal. The company cautioned that the study assessed a single dose and that comparisons with other treatments are cross-trial.
• The company plans to advance ABCL635 into late-stage development in 2027 and expects to release 12-week and open-label extension data in early 2027. It also plans to study the drug for treatment-related hot flashes in breast and prostate cancer patients, while a longer-acting follow-on, ABCL992, entered IND-enabling work.
• After completing an oversubscribed $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and over $890 million in available liquidity including committed government funding. Management said it has funding for at least three years of pipeline investment.
• AbCellera added three programs—ABCL992, an oncology program, and an ion-channel-targeting antibody—and said ABCL688 and ABCL386 remain in IND-enabling work, with both potentially entering clinical trials in 2027.
• Despite favorable Phase I tolerability and pharmacokinetic results for ABCL575, AbCellera does not plan to advance it beyond Phase I, citing setbacks for other drugs targeting the OX40/OX40L pathway.

AbCellera Biologics Price Performance

Shares of NASDAQ:ABCL traded up $0.62 during mid-day trading on Monday, hitting $12.50. The company had a trading volume of 2,945,557 shares, compared to its average volume of 5,858,420. The firm has a fifty day moving average price of $12.28 and a 200 day moving average price of $7.04. The company has a market capitalization of $3.83 billion, a PE ratio of -23.15 and a beta of 1.59. AbCellera Biologics has a one year low of $2.74 and a one year high of $15.02.

Analyst Upgrades and Downgrades

ABCL has been the topic of several recent analyst reports. The Goldman Sachs Group began coverage on shares of AbCellera Biologics in a report on Thursday, September 24th. They issued a "neutral" rating and a $13.00 target price on the stock. JPMorgan Chase & Co. began coverage on AbCellera Biologics in a report on Tuesday, September 29th. They set an "overweight" rating and a $17.00 price target for the company. Jefferies Financial Group assumed coverage on AbCellera Biologics in a research report on Friday, October 30th. They issued a "buy" rating and a $21.00 price objective for the company. UBS Group assumed coverage on AbCellera Biologics in a research note on Monday, October 12th. They issued a "buy" rating and a $18.00 price objective on the stock. Finally, Stifel Nicolaus upped their target price on AbCellera Biologics from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.78.

About AbCellera Biologics

AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease.

The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.